Nanoparticles in Medicine: Therapeutic Applications and Developments

By L. Zhang, F. Gu, Juliana M. Chan, Andrew Z. Wang, Robert Langer, O. Farokhzad. Clinical pharmacology and therapy, 2008

2,553 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Electronic, Optical and Magnetic Materials

View Paper: https://www.semanticscholar.org/paper/3b2355773720106653363b02f93d12d72f91ad25

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

In Biomedical Engineering

In Electronic, Optical and Magnetic Materials

Citations in the corpus

Development of nanoparticles for antimicrobial drug delivery. (2010, background): “number of nanoparticle-based drug delivery systems have been approved for clinical uses to treat a variety of diseases and many other therapeutic nanoparticle formulations are currently under various stages of clinical tests [4, 7].”
Enzyme-responsive nanoparticles for drug release and diagnostics. (2012, background): “Because of their biocompatibility and ease of fabrication, liposomes have been widely utilized in drug delivery and a number of liposomal drugs have been clinically approved and are now commercially available [41].”
Biosynthesis of silver and zinc oxide nanoparticles using Pichia fermentans JA2 and their antimicrobial property (2014, methodology): “Nanoparticles have been abundantly used in nanochemistry to enhance the immobilization and activity of catalysts (Wang 2006) in pharmaceutical nanoengineering for delivery of therapeutic agents (Zhang et al. 2008) in chronic disease diagnostics and in sensors (Hong et al. 2008).”
pH-sensitive nano-systems for drug delivery in cancer therapy. (2014, background): “In recent decades, a myriad of nanoscale DDSs have been developed for better therapeutic applications (Wang and Zhang, 2012; Zhang et al., 2008).”
Biocompatibility of engineered nanoparticles for drug delivery. (2013, neutral): “(Myocet®), immunopotentiating reconstituted influenza virosome (Epaxal®) [171].”
Advances and Challenges of Liposome Assisted Drug Delivery (2015, background): “The use of PEG significantlyminimizes, but does not completely circumvent, liposomal uptake by the RES—with pathways independent of opsonization also possible (Laverman et al., 2001; Sawant and Torchilin, 2012).”
Antibacterial Activity of Green Synthesis of Iron Nanoparticles Using Lawsonia inermis and Gardenia jasminoides Leaves Extract (2015, background): “The widespread practical application of metal nanoparticles (<100 nm) is attributable to a number of their unique properties [2–5].”
Zinc Oxide Nanoparticles for Selective Destruction of Tumor Cells and Potential for Drug Delivery Applications (2010, background): “Onco TCS [115] Liposomal vincristine Non-Hodgkin’s lymphoma Inex, Enzon Phase II/III NX 211 [116] Liposomal lurtotecan Solid tumors Gilead Phase II Panzem NCD [117] 2-methoxyestradiol Nanocrystal Glioblastoma EntreMed Phase II OSI-211 [115] Liposomal lurtotecan Ovarian cancer OSI Pharmaceuticals Pha”
Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. (2008, methodology): “Several liposomal drug formulations have been approved for clinical use, including Doxil (doxorubicin liposomes)(13) which was first to be approved in 1995, AmBisome (amphotericin B liposomes), DaunoXome (daunorubicin liposomes), DepoCyt (cytarabine liposomes), DepoDur (morphine liposomes), and Visu”
Designing materials to direct stem-cell fate (2009, background): “This could be achieved by forming a scaffold that leads to timed drug (small chemical) or biomolecule delivery near a stem-cell niche or by targeted delivery of soluble microparticles or nanoparticles as carriers of such bioactive niche component”
Assessment of the Evolution of Cancer Treatment Therapies (2011, background): “[53] reported on 15 clinical trials being conducted for nanoparticle-based therapeutics.”